Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Amy S, Rosenberg"'
Autor:
Aimee E. Mattei, Andres H. Gutierrez, Soorya Seshadri, Jacob Tivin, Matt Ardito, Amy S. Rosenberg, William D. Martin, Anne S. De Groot
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
In silico immunogenicity risk assessment has been an important step in the development path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a given biologic is ‘fully human’, T cell epitopes that are contain
Externí odkaz:
https://doaj.org/article/d3ac97f35912434aae9b77e2b10534c0
Autor:
Ankit K. Desai, P. Brian Smith, John S. Yi, Amy S. Rosenberg, Trevor D. Burt, Priya S. Kishnani
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
IntroductionThe efficacy of enzyme replacement therapy (ERT) with alglucosidase alfa for infantile-onset Pompe disease (IOPD) is limited in some patients due to the development of high and sustained antibody titers (HSAT; ≥12,800).MethodsWe carried
Externí odkaz:
https://doaj.org/article/ec2469dc10d54eddb7249c22c74a9079
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/57b6ca729a84466c935bfa6e4d54bdcc
Autor:
Lai Xu, Helen Luo, Rong Wang, Wells W. Wu, Je-Nie Phue, Rong-Fong Shen, Hartmut Juhl, Leihong Wu, Wei-lun Alterovitz, Vahan Simonyan, Lorraine Pelosof, Amy S. Rosenberg
Publikováno v:
BMC Medical Genetics, Vol 20, Iss 1, Pp 1-13 (2019)
Abstract Background Reference genes are often interchangeably called housekeeping genes due to 1) the essential cellular functions their proteins provide and 2) their constitutive expression across a range of normal and pathophysiological conditions.
Externí odkaz:
https://doaj.org/article/4139dfba11ea48ae9b6493a2f0e9f38d
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Externí odkaz:
https://doaj.org/article/eae2a3670ea84f6b944468b1496bba5f
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Immune tolerance induction (ITI) with a short-course of rituximab, methotrexate, and/or IVIG in the enzyme replacement therapy (ERT)-naïve setting has prolonged survival and improved clinical outcomes in patients with infantile Pompe disease (IPD) l
Externí odkaz:
https://doaj.org/article/fbf3bf99db7b43d297804966c991cb7a
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
The first case of human transmission of SARS-CoV-2 was reported in China in December 2019. A few months later, this viral infection had spread worldwide and became a pandemic. The disease caused by SARS-CoV-2, termed COVID-19, is multifactorial and a
Externí odkaz:
https://doaj.org/article/cebd0684036d4179b8d7cb905e9d6c75
Autor:
Lai Xu, Lorraine Pelosof, Rong Wang, Hugh I. McFarland, Wells W. Wu, Je-Nie Phue, Chun-Ting Lee, Rong-Fong Shen, Hartmut Juhl, Lei-Hong Wu, Wei-Lun Alterovitz, Emanuel Petricon, Amy S. Rosenberg
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
To evaluate the expression of immune checkpoint genes, their concordance with expression of IFNγ, and to identify potential novel ICP related genes (ICPRG) in colorectal cancer (CRC), the biological connectivity of six well documented (“classical
Externí odkaz:
https://doaj.org/article/3f067d4684b54e6e887a0e30459c6914
Autor:
Aimee E. Mattei, Andres H. Gutierrez, William D. Martin, Frances E. Terry, Brian J. Roberts, Amy S. Rosenberg, Anne S. De Groot
Publikováno v:
Front Drug Discov (Lausanne)
Thein silicoprediction of T cell epitopes within any peptide or biologic drug candidate serves as an important first step for assessing immunogenicity. T cell epitopes bind human leukocyte antigen (HLA) by a well-characterized interaction of amino ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2baaa46b957845b176edb5c7c9f65bbd
https://doi.org/10.3389/fddsv.2022.952326
https://doi.org/10.3389/fddsv.2022.952326
Autor:
Baodong Sun, Suhrad G. Banugaria, Sean N. Prater, Trusha T. Patel, Keri Fredrickson, Douglas J. Ringler, Antonin de Fougerolles, Amy S. Rosenberg, Herman Waldmann, Priya S. Kishnani
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 1, Iss C, Pp 446-450 (2014)
Approximately 35–40% of patients with classic infantile Pompe disease treated with enzyme replacement therapy (ERT) develop high, sustained antibody titers against the therapeutic enzyme alglucosidase alfa, which abrogates the treatment efficacy. I
Externí odkaz:
https://doaj.org/article/e2218e4187334a8baee1035af47e2f37